Of the U.S. biopharmaceutical companies currently developing treatments or vaccines targeting the COVID-19 infection caused by coronavirus , Vir Biotechnology Inc. 's shares have increased by 279 percent as they are in the midst of preclinical testing monoclonal antibodies as a treatment for this disease . This statistic shows the year-to-date stock performance of select biopharmaceutical companies working on COVID-19 treatments or vaccines in the U.S. as of March 11 , 2020 .
